Search clinical trials for: metastatic non-small cell lung cancer

Total 158256 results

Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
BeiGene

Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China, Georgia, Moldova, Republic of
DualityBio Inc.

Recruiting

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumors

United States, Australia
DualityBio Inc.

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
Hospices Civils de Lyon

Recruiting

Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells) (LUTON)

Non Small Cell Lung Cancer

France
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Head and Neck Cancer | Esophageal Cancer | Lung Cancer | Precancerous Condition

United States
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Melanoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Bone Cancer | Rectal Cancer | Uterine Sarcoma | Colon Cancer | Ovarian Sarcoma | Eye Cancer | Adult Soft Tissue Sarcoma

United States
Incyte Corporation
AstraZeneca

Active, not recruiting

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Lung Cancer

United States, Korea, Republic of, Spain, Taiwan
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306)

Non-small Cell Lung Cancer (NSCLC)
Incyte Corporation

Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Metastatic Melanoma | Unresectable Melanoma | Metastatic Urothelial Cancer | Metastatic Non-small Cell Lung Cancer | Locally Advanced Renal Cell Carcinoma | Locally Advanced Urothelial Cancer | Metastatic Clear-Cell Renal Cell Carcinoma

France, Spain, United States, Italy, Austria, Romania, Poland, Hungary
AstraZeneca

Completed

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)

United States
Checkpoint Therapeutics, Inc.

Terminated

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO)

Metastatic Non-squamous Non Small Cell Lung Cancer

Peru, Russian Federation, South Africa, New Zealand, Georgia, Thailand, Brazil, Malaysia
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Incyte Corporation

Completed

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Solid Tumor

United States
WindMIL Therapeutics
Bristol-Myers Squibb

Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic

United States
Incyte Corporation

Terminated

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Solid Tumors

United States
Incyte Biosciences International Sàrl

Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States, Belgium, Australia, Spain
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Lung Cancer

Spain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Squamous Non-Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Brazil, Canada, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, P... and more
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
Incyte Biosciences International Sàrl

Completed

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States, United Kingdom, Spain, Switzerland
Incyte Corporation

Withdrawn

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors | Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

ALK-positive Non-small Cell Lung Cancer

United States, France, Italy, United Kingdom, Taiwan, Turkey, Belgium, Germany, Canada, Singapore, Spain, Korea, Republic of, Netherlands, Russian Federation, Brazil, Hong Kong, Australia
Sichuan Cancer Hospital and Research Institute
Mianyang Central Hospital; Cancer Hospital of Guizhou Province

Unknown

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC） (OITROLC)

Oligo-metastatic Stage IV Non-small Cell Lung Cancer

China
Centre Georges Francois Leclerc
AstraZeneca

Terminated

Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas (CTC-Poumon)

Non-small Cell Lung Cancer Metastatic

France
Rennes University Hospital
Roche Pharma AG; National Research Agency, France

Completed

BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology (BMS_PD-L1)

Hodgkin Lymphoma | Non-small Cell Lung Cancer | Diffuse Large B-cell Lymphoma | Metastatic Breastcancer

France
AbbVie

Completed

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Lung Cancer | Adenocarcinoma of the Lung
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
Altor BioScience
National Cancer Institute (NCI)

Completed

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Hannover Medical School

Terminated

Taxotere-Enoxaparin-(ENOXA)-Study

Non-small Cell Lung Cancer

Germany
Sun Yat-sen University

Unknown

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (SEQUENCE)

Non Small Cell Lung Cancer

China
Celldex Therapeutics

Completed

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Marginal Zone B Cell Lymphoma) | Any T-cell Malignancy | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | Hormone-refractory Prostate Adenocarcinoma, Ovarian... and other conditions

United States

Search clinical trials for: metastatic non-small cell lung cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations